Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

BACKGROUND: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened b...

Descripción completa

Detalles Bibliográficos
Autores principales: Forni, Valentina, Bianchi, Giorgia, Ogna, Adam, Salvadé, Igor, Vuistiner, Philippe, Burnier, Michel, Gabutti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733800/
https://www.ncbi.nlm.nih.gov/pubmed/23870287
http://dx.doi.org/10.1186/1471-2369-14-157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733800/
https://www.ncbi.nlm.nih.gov/pubmed/23870287
http://dx.doi.org/10.1186/1471-2369-14-157

Ejemplares similares